Business Context and Reporting Period
This Form 8-K filing by DexCom, Inc. covers the date of September 10, 2026. The report details a corporate governance change involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased its size to thirteen directors.
- New Appointment: Glenn S. Boehnlein was appointed as a director, effective immediately.
- Committee Assignments: Mr. Boehnlein was appointed to the Operations & Innovation Committee and the Audit Committee.
- Independence: The Board determined Mr. Boehnlein qualifies as an independent director under applicable securities laws and Nasdaq listing standards.
Compensation and Governance Details
- Initial Equity Grant: Mr. Boehnlein received an initial grant of Restricted Stock Units (RSUs) with a fair value of $500,000. These vest annually over three years, subject to continued service.
- Annual Equity Grant: He is eligible for an annual RSU grant with a fair value of $347,500 around the 2027 Annual Meeting. This award vests on the earlier of the first annual stockholder meeting thereafter or one year from the grant date.
- Change in Control: Vesting of outstanding equity awards for non-employee directors accelerates in full upon a change in control of DexCom.
- Indemnification: Mr. Boehnlein entered into the Company's standard indemnity agreement for directors and executive officers.
Investor Verification Checklist
- Verify the independence status of Glenn S. Boehnlein against current Nasdaq listing standards.
- Review the specific vesting schedules and performance conditions attached to the $500,000 initial RSU grant.
- Confirm the composition of the Audit Committee and Operations & Innovation Committee following this appointment.
- Check for any undisclosed material relationships between Mr. Boehnlein and the Company as required by Item 404(a) of Regulation S-K.